© May 2026 | IJIRT | Volume 12 Issue 12 | ISSN: 2349-6002

Role of Vaccines in Emerging Infectious Diseases: Advances, Challenges, and Future Perspectives

Ajay T.[1], Thamaraieniyan A. S.[2], Kalaivani R.[3], Nepolean R.[4], A. Aafreen[5], Aishwar J. P.[6]
[1,2,3,4,5,6] *Thanthai Roever college of pharmacy*

Abstract—**Emerging infectious diseases (EIDs) remain a burden to the global health system in terms of being unpredictable, spreading at a high rate, and strongly driven by the complex ecological factors. Vaccination is still the foundation of the prevention, but the COVID-19 pandemic has helped to see the potential of vaccines, as well as the limitations of the existing strategies. The review is also a critical analysis of the latest developments in the field of vaccine technologies, their application in real-life outbreak situations, and the ongoing challenges of unequal access, antigenic drift, and sociopolitical issues. The paper also identifies future directions such as universal vaccines; design assisted by AI and integrated One Health paradigms. There is a critical approach taken through out to evaluate whether the current innovations are enough to tackle the future pandemic threats.**

I. INTRODUCTION

The biological, environmental and sociopolitical factors combined together provide the factors which contribute to the emerging infectious diseases. Although the spill over of zoonotic is highlighted, it is also important to focus on how anthropogenic alteration, including, but not limited to, deforestation, industrialized agriculture, and global warming contribute to the increased pace of the pathogen outbreak. Conventional interventions in the field of public health such as the surveillance, quarantine as well as therapeutics are reactionary. Vaccines, in their turn, provide a proactive approach. Nevertheless, the belief that vaccines should be able to regulate EIDs should be questioned. The COVID-19 pandemic has shown how so much can be done to show that despite the rapid development of vaccines, the distribution timeline, vaccine nationalism, and a lack of confidence among the population can ruin the efforts. In such a way, vaccines should be viewed as a part of a larger system comprising governance, infrastructure, and behavioral dynamics.

II. ADVANCES IN VACCINE TECHNOLOGIES

2.1 mRNA Vaccines

mRNA vaccines can be described as a paradigm shift because of its rapid development process and flexibility. They do not require the culture of pathogens, unlike the traditional platforms and shorten the production timelines significantly. Nevertheless, they are dependent on cold-chain logistics and comparatively high production costs, which comes with scalability issues in low-resource contexts. Most importantly, as mRNA vaccines demonstrated great effectiveness in case of the original SARS-CoV-2 strain, the decrease in immunity and the inefficacy against the variants demonstrate the constraints in terms of longevity. The question it creates is whether mRNA platforms are to be supplemented using alternative methods like mucosal vaccinations to enhance better transmission control.

2.2 Viral Vector Vaccines

Viral vector vaccines have superior immune responses and are easier to store than mRNA vaccines. Efficacy can be, however, decreased by prior immunity to vector viruses. Also, the infrequent occurrence of adverse events, including vaccine-induced thrombotic thrombocytopenia (VITT), has impacted societal perception and regulations. This brings out a larger problem that is the speed versus long term safety data trade-off when deploying vaccines in an emergency. Although these trade-offs are acceptable in times of crisis, they can undermine the confidence of the head of state unless clearly communicated.

2.3 Protein Subunit and Recombinant Vaccines

Protein based vaccines are well established and have good safety profiles and can be used widely even in vulnerable populations. But their longer development cycles restrict their usefulness in emergencies. Critically, they might be more of a complement than a first line in a pandemic environment, potentially being as booster alternatives or in those populations where the more recent technologies are less accepted.

2.4 DNA Vaccines
In theory, DNA vaccines may have an advantage in stability and cost, but have low immunogenicity in humans, which has impeded mass application. New methods of delivery (e.g., electroporation) can mitigate this limitation, although questions of scalability are unsettled.

2.5 Rapid Vaccine Development Platforms
Platform technologies have changed preparedness by providing the ability of plug-and-play. Nevertheless, the regulatory schemes have not been in line with such innovations, as many of them demand unnecessary testing even where the platforms are similar. Such regulatory lapse can slow down implementation in any future emergency.

III. ROLE OF VACCINES IN CONTROLLING EMERGING INFECTIOUS DISEASES

3.1 Outbreak Response
Vaccines are also very useful in the containment of outbreaks as observed with Ebola. Their effectiveness is, however, normally limited by the time of implementation. Vaccines do not always have an immediate impact as they are administered after they have reached their peak of transmission in most instances. This implies that pre-approved vaccine libraries against high-risk pathogens would have a considerable impact on responsiveness with respect to investment.

3.2 Herd Immunity
Herd immunity is a more complicated concept in EIDs than in endemic disease. The rates of mutation and asymmetrical vaccine coverage can eliminate the stability of herd immunity, as we have seen with COVID-19. Therefore, herd immunity can be an impractical policy objective when dealing with some pathogens, requiring perpetual immunization policies.

3.3 Prevention of Zoonotic Spillover
Animal reservoir vaccination is a little used strategy. Large-scale animal vaccination is challenging, both logistically and ecologically, although theoretically effective. In addition, there may be no economic justification to such interventions.

3.4 Pandemic Preparedness
International efforts such as CEPI have enhanced preparedness, but there are coordination gaps. The COVID-19 response demonstrated a lack of coordination in international health governance, indicating that technological improvements should be accompanied by changes in institutions.

IV. CHALLENGES IN VACCINE DEVELOPMENT AND DEPLOYMENT

4.1 Rapid Mutation of Pathogens
RNA viruses have antigenic drift and shift, making it difficult to design the vaccine. Existing measures are usually not up to the influx of new viruses, so the solutions provided will be updated periodically and not a planned response.

4.2 Regulatory and Ethical Issues
EUAs were found to expedite the availability of vaccines, but they created transparency and long-term safety concerns. Issues of ethical dilemma also arose in terms of trial designs and the use of placebo in times of pandemics.

4.3 Vaccine Hesitancy
Hesitancy is not a misinformation product only, as it carries with it more profound problems, like mistrust of institutions and historical injustices. To overcome reluctance, sociological and cultural methods, not scientific communication, are necessary.

4.4 Global Inequity
One of the biggest obstacles to the control of EIDs is still vaccine inequity. Most of the initial supplies of COVID-19 vaccines were taken by high-income nations, exposing low-income regions. This does not only create ethical issues, but also increases pandemics because it has given the viruses an opportunity to transmit and mutate.

4.5 Cold Chain and Distribution
Sophisticated vaccines usually need ultra-cold conditions, which is not feasible in most areas. Thermostable innovations in formulations are required in order to make them globally available.

V. FUTURE PERSPECTIVES

5.1 Universal Vaccines
Universal vaccines seek to have a wide and long-term protection with targeting of conserved areas of pathogens. Although promising, one of the key scientific issues is to obtain adequate immunogenicity against conserved epitopes.

5.2 Personalized Vaccination Strategies
Individualizing vaccines on the basis of genetic and immunological data may enhance efficacy, however, at what cost, is it feasible and is it equitable.

5.3 Artificial Intelligence in Vaccine Design
AI has the potential to speed up the process of antigen discovery and optimise vaccine candidates. Nonetheless, it is highly reliant on the quality of data and cooperation among interdisciplinary teams, which not always is uniform across regions.

5.4 Global Collaboration
The further prosperity will be based on fair relations instead of a top-down aid system. Sustainable preparedness depends on technology transfer and local manufacturing capacity.

5.5 One Health Approach
A combination of human, animal, and environmental health offers a holistic approach in the prevention of EIDs. Nonetheless, the achievement of operationalization of One Health is hard as the governance and funding systems are disjointed.

VI. CONCLUSION

Vaccines are essential and not full in themselves to fight new infectious diseases. The improvements in technology have greatly enhanced the possibilities of responding, but some systemic issues hamper the possibilities of technological advancement, including inequity, failure of governance, and so on. It is necessary to have a multidisciplinary and globally coordinated approach so that the future vaccine strategies can be scientifically advanced, socially, and ethically sound.

REFERENCES

[1] World Health Organization, Draft Landscape of COVID-19 Candidate Vaccines, 2020.
[2] F. Krammer, “SARS-CoV-2 vaccines in development,” Nature, 2020.
[3] F. P. Polack et al., “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine,” New England Journal of Medicine, 2020.
[4] L. R. Baden et al., “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine,” New England Journal of Medicine, 2021.
[5] B. S. Graham, “Rapid COVID-19 vaccine development,” Science, 2020.
[6] S. Plotkin, “History of vaccination,” Proceedings of the National Academy of Sciences, 2014.
[7] CEPI, 100 Days Mission to Respond to Future Pandemics, 2021.
[8] L. Corey et al., “A strategic approach to COVID-19 vaccine R&D,” Science, 2020.
[9] D. E. Bloom et al., “Vaccines for emerging infectious diseases,” Proceedings of the National Academy of Sciences, 2017.
[10] A. S. Fauci, “Emerging infectious diseases: A 10-year perspective,” Emerging Infectious Diseases Journal, 2020.